Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

February 04, 2010

FORM 4				OMB APPROVAL		
	UNITED STATES	S SECURITIES AND EXCHANGI Washington, D.C. 20549	E COMMISSION	OMB Number:	3235-0)287
Check this box if no longer subject to Section 16. Form 4 or	STATEMENT O	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES				
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						0.5
(Print or Type Respon	ses)					
Name and Address McCorkle Dougla	s of Reporting Person * as S	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Issuer	Reporting Pers	son(s) to	

			PHARMACEUTICALS INC	(Check all applicable)			
			[REGN]	Director 10% Owner			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction	_X_ Officer (give title Other (specify below)			
			(Month/Day/Year)	VP Controller and Asst Treasur			
777 OLD SAW MILL RIVER			02/02/2010				

/// OLD SAW MILL RIVER **ROAD**

> (Street) 4. If Amendment, Date Original Filed(Month/Day/Year)

REGENERON

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person

TARRYTOWN, NY 10591

(City)	(State) (Zip) Table	e I - Non-D	erivative s	Secur	ities Acqu	uired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction(A) or Dispo Code (Instr. 3, 4 a (Instr. 8)		4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common	00/00/00/10		Code V	Amount	or (D)	Price	(Instr. 3 and 4)	D	
Stock	02/02/2010		M <u>(1)</u>	4,000	A	11.64	4,000	D	
Common Stock	02/02/2010		S <u>(1)</u>	4,000	D	\$ 28	0	D	
Common Stock	02/02/2010		M(1)	1,875	A	\$ 9.49	1,875	D	
Common Stock	02/02/2010		S <u>(1)</u>	1,875	D	\$ 28	0	D	
							3,424	I	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common By 401(k) Stock Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)	\$ 9.49	02/02/2010		M(1)	1,875	(2)	12/15/2014	Common Stock	1,875
Incentive Stock Option (right to buy)	\$ 11.64	02/02/2010		M <u>(1)</u>	4,000	<u>(4)</u>	12/19/2015	Common Stock	4,000

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

McCorkle Douglas S 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

VP Controller and Asst Treasur

Signatures

/s/**Douglas S. McCorkle

02/03/2010

Date

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- (2) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (3) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.
- (4) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3